How does PT-141 work?

PT-141, or bremelanotide, is a melanocortin receptor agonist. It acts centrally on melanocortin pathways involved in desire, notably MC4R, rather than on genital blood flow the way PDE5 inhibitors do. Half-life on this site's profile is about 2.7 hours. Molecular weight is 1,025.2 daltons. Approval as Vyleesi in June 2019 covers hypoactive sexual desire disorder in premenopausal women, based on RECONNECT in 1,267 women over 24 weeks: desire scores rose by 0.35 on the integrated FSFI desire scale versus placebo, with nausea, flushing, and headache each in 10% or more. The label warns of a transient rise in blood pressure after each dose. Use in men is off label. A research-chemical vial is not that labeled pen. This FAQ does not invent a dose. Full record at /compounds/pt-141.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of sexual health and hormone peptides. PT-141, melanotan, oxytocin, gonadorelin, and kisspeptin-10.